Caring Ambassadors Hepatitis C Program Newsletter

June 2010

Clinical Trials, Cohort Studies, Pilot Studies

Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Boonwaat L, Haber PS, Levy MH, Lloyd AR. Med J Aust. 2010 May 3;192(9):496-500.

Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Rawlins SR, El-Zammar O, Zinkievich JM, Newman N, Levine RA. Dig Dis Sci. 2010 May 12. [Epub ahead of print]

Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study. Zarski JP, Sturm N, Desmorat H, et al. Liver Int. 2010 May 21. [Epub ahead of print]

Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alam I, Stainbrook T, Cecil B, Kistler KD. Aliment Pharmacol Ther. 2010 May 25. [Epub ahead of print]

Identifying HCV genotype 1 patients at risk of relapse. Deschênes M, Bain VG, Lee SS, et al. Eur J Gastroenterol Hepatol. 2010 May;22(5):546-51.

Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?

Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. J Med Virol. 2010 May;82(6):958-64.

Hepatitis C virus infection, age, and hispanic ethnicity increase mortality from liver cancer in the United States. Younossi ZM, Stepanova M. Clin Gastroenterol Hepatol. 2010 May 17. [Epub ahead of print]

Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis c virus-related cirrhosis. Ziol M, Nault JC, Aout M, et al. Gastroenterology. 2010 May 19. [Epub ahead of print]

Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Wise M, Finelli L, Sorvillo F. Public Health Rep. 2010 May-Jun;125(3):414-22.

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Sood A, Sobti P, Midha V, et al. Indian J Gastroenterol. 2010 Mar;29(2):62-5. Epub 2010 May 5.

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia. Saadoun D, Resche Rigon M, Sene D, et al. Blood. 2010 May 3. [Epub ahead of print]

Thyroid function outcomes following pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Tran HA, Reeves GE, Ianna EA, Leembruggen N. Endocr Pract. 2010 May 3:1-16. [Epub ahead of print]

Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis c infection. Lim C, Olson J, Zaman A, Phelps J, Ingram KD. J Clin Gastroenterol. 2010 May 20. [Epub ahead of print]

Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. Liu SS, Schneekloth TD, Talwalkar JA, et al. J Clin Gastroenterol. 2010 May 20. [Epub ahead of print]

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. Levast M, Larrat S, Thelu MA, et al. J Med Virol. 2010 May;82(5):747-54.

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Yu ML, Lee CM, Chuang WL, et al. J Infect Dis. 2010 May 18. [Epub ahead of print]

Basic and Applied Science, Pre-Clinical Studies

Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. Mosbruger TL, Duggal P, Goedert JJ, et al. J Infect Dis. 2010 May 1;201(9):1371-80.

La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication. Shirasaki T, Honda M, Mizuno H, et al. J Infect Dis. 2010 May 24. [Epub ahead of print]

Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics. Smolic R, Smolic M, Andorfer JH, Wu CH, Smith RM, Wu GY. World J Gastroenterol. 2010 May 7;16(17):2100-8.

Regulation of PKR by HCV IRES RNA: Importance of Domain II and NS5A. Toroney R, Nallagatla SR, Boyer JA, Cameron CE, Bevilacqua PC. J Mol Biol. 2010 May 4. [Epub ahead of print]

HCV NS5A activates the mammalian target of rapamycin (mTOR) pathway contributing to cell survival via disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. Lu P, Liang D, Tong W, Li J, Yuan Z. J Biol Chem. 2010 May 3. [Epub ahead of print]

HIV/HCV Coinfection

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Rallón NI, Naggie S, Benito JM, et al. AIDS. 2010 May 15;24(8):F23-9.

Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Cherry CL, Affandi JS, Brew BJ, et al. Neurology. 2010 May 11;74(19):1538-42.

Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. Baum MK, Sales S, Jayaweera DT,et al. HIV Med. 2010 May 23. [Epub ahead of print]

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. J Med Virol. 2010 May;82(5):791-8.

Stronger hepatitis C virus-specific CD8(+) T-cell responses in HIV coinfection. Barrett L, Gallant M, Howley C, Ian Bowmer M, Hirsch G, Peltekian K, Grant M. J Viral Hepat. 2010 May 20. [Epub ahead of print]

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. Macías J, Mira JA, Gilabert I, et al. HIV Med. 2010 May 17. [Epub ahead of print]

Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C Virus coinfection treated with ribavirin and highly active antiretroviral therapy. Reiberger T, Kosi L, Maresch J, et al. J Infect Dis. 2010 May 20. [Epub ahead of print]

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. Potter M, Odueyungbo A, Yang H, et al. AIDS. 2010 May 14. [Epub ahead of print]

Complementary and Alternative Medicine

Nutrigenomics Therapy of Hepatisis C Virus Hepatosteatosis. Qing L, Bengmark S, Shen Q. BMC Gastroenterol. 2010 May 20;10(1):49. [Epub ahead of print]

Epidemiology, Diagnostics, and Miscellaneous Works

Hepatocellular carcinoma - United States, 2001-2006. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 May 7;59(17):517-20.

Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.

Bukh J, Meuleman P, Tellier R, et al. J Infect Dis. 2010 May 1;201(9):1381-9.

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Lewis- Ximenez LL, Lauer GM, Schulze Zur Wiesch J, et al. Clin Infect Dis. 2010 May 1;50(9):1222-30.

Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.

Southern WN, Drainoni ML, Smith BD, et al. J Viral Hepat. 2010 May 20. [Epub ahead of print]

Hepatitis C virus risk behaviors within the partnerships of young injecting drug users.

Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Addiction. 2010 May 14. [Epub ahead of print]

Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. Boodram B, Golub ET, Ouellet LJ. Drug Alcohol Depend. 2010 May 14. [Epub ahead of print]